June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Cotton-Tip Applicator Lid Retraction Intravitreal Injections and Cataract Associations
Author Affiliations & Notes
  • joseph James raevis
    Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York, United States
  • Amirfarbod Yazdanyar
    Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York, United States
  • Johnny Xiang Li
    Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York, United States
  • Azam Zaki
    Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York, United States
  • Fahd Yazdanie
    Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York, United States
  • Eric Shrier
    Ophthalmology, SUNY Downstate Medical Center, Brooklyn, New York, United States
  • Footnotes
    Commercial Relationships   joseph raevis, None; Amirfarbod Yazdanyar, None; Johnny Li, None; Azam Zaki, None; Fahd Yazdanie, None; Eric Shrier, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5724. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      joseph James raevis, Amirfarbod Yazdanyar, Johnny Xiang Li, Azam Zaki, Fahd Yazdanie, Eric Shrier; Cotton-Tip Applicator Lid Retraction Intravitreal Injections and Cataract Associations. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5724.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The cotton-tip applicator (CTA) method for lid retraction is a new technique for elevating the eyelid during intravitreal injections and one that has yet to be fully established as equivalent to other methods. We describe the first retrospective, observational clinical study to examine the effects that superior temporal intravitreal injections have on cataract development and intraocular pressure (IOP) changes after cataract surgery.

Methods : We performed a retrospective chart review of 479 consecutive charts from patients receiving superior temporal quadrant intravitreal injections of Bevacizumab and Aflibercept using the CTA Technique. Of these patients, 263 had multiple intravitreal injections and were included in this study. The reason for intravitreal therapy, preoperative and postoperative IOP, cataract development that required surgery, and best corrected visual acuity (BCVA) were collected for all patients.

Results : Of the 263 patients examined, 18 patients developed a total of 24 visually significant cataracts that warranted surgery. African Americans comprised 53% of the patients in this study, with Caucasians, Hispanics and Asians representing 30%, 10% and 4% respectively. Males and females were equally represented at 50%, but 15 cataracts developed in males while 9 cataracts developed in females (p= 0.22), no cataracts developed within 1 week of intravitreal therapy. Diabetic macular edema, macular degeneration, and vein occlusions were the most common indications for therapy, accounting for 38%, 37% and 20% of patients respectively. After cataract surgery, the average IOP declined by 2.2mmHg (SD pre-OP= 4.7, SD post-OP= 3.1, p= 0.04, Figure 1) while the average BCVA improved from a mean logMAR 0.81 to 0.78 (SD pre-OP= 0.77, SD post-OP= 0.71, p= 0.80).

Conclusions : Intravitreal injections in the superior temporal quadrant with the CTA method for lid retraction did not lead to any increase in cataracts due to lenticular damage from the injection. When cataracts did form after intravitreal therapy with Bevacizumab or Aflibercept, there was a significant drop in IOP but not a significant improvement in the BCVA which is likely due to the underlying pathology.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×